Syndopa CR 50 200 mg
Available Dosages
| SKU | 186 |
|---|---|
| Generic For | Sinemet CR |
| Strength | 50 + 200 mg |
| Manufacturer | Wyeth Pharmaceuticals |
| Active Ingredient | Carbidopa Levodopa |
| Pack Size | Qty | Price Per Pill or Unit | Price | Cart | |
|---|---|---|---|---|---|
| 30 Tablet/s | US$ 0.47 | US$ 14.00 | |||
|
|||||
| 60 Tablet/s | US$ 0.30 | US$ 18.0036%US$ 28.00 | |||
|
|||||
| 90 Tablet/s | US$ 0.28 | US$ 25.0040%US$ 42.00 | |||
|
|||||
Syndopa CR 50 200 mg (Carbidopa Levodopa) – Affordable Sinemet CR Alternative
Syndopa CR 50 200 mg is a controlled-release formulation that combines Carbidopa 50 mg and Levodopa 200 mg as the active ingredients. It is primarily used in the management of Parkinson’s disease and Parkinsonian-related symptoms, such as muscle stiffness, tremors, trouble maintaining balance, and slowness of movement. Levodopa is converted into dopamine, whose deficiency in the brain is the key factor behind Parkinson’s symptoms. By replenishing dopamine levels, Levodopa eases motor difficulties.
On the other hand, Carbidopa works to prevent the premature breakdown of Levodopa in the blood. Automatically, most of the Levodopa would convert into dopamine outside the brain, resulting in side effects and reduced effectiveness. Carbidopa ensures more Levodopa reaches the brain, thereby increasing effectiveness and reducing side effects such as nausea and vomiting. The controlled-release formulation is specially designed for the gradual release of the medication into the body, offering longer-lasting symptomatic relief. The combination helps restore the balance of dopamine in the brain, thereby improving the mobility and quality of life for patients with this chronic neurological disorder. Syndopa CR 50/200 is often recommended when Parkinson’s medications are not sufficient or when a controlled, sustained release of Levodopa is needed.
Things to take care of while using Syndopa CR 50 200 mg
Before initiating treatment with Syndopa CR 50/200mg, patients should inform their healthcare provider of their medical history and current medications. Key precautions include:
- Allergic reactions: Avoid taking Syndopa CR if you are allergic to Levodopa, Carbidopa or any other ingredients in the medicine.
- Pre-existing conditions: Use cautiously in patients with heart disease, liver or kidney impairment, peptic ulcer, asthma, glaucoma, seizures, or depression.
- Pregnant and breastfeeding: The safety and effectiveness of this medication have not been fully established. It should only be used in such cases if prescribed by a healthcare professional after weighing the benefits.
- Alcohol: Limit or avoid alcohol consumption as it may increase dizziness and drowsiness.
- Driving and machinery: The medication can contribute to dizziness and sudden episodes of sleep disorders. Therefore, the patient needs to exercise caution when driving or operating heavy machines at home.
- Drug interactions: Syndopa CR 50/200mg may interact with certain medications, including antihypertensive agents, antipsychotic drugs, iron supplements, and other anti-nausea medications. Be sure to inform your healthcare professional about your ongoing treatment. Like all pharmaceutical agents, the Levodopa/Carbidopa combination can cause adverse effects, although not everyone gets them.
Side effects of th Syndopa CR 200mg
Commonly reported side effects are nausea, vomiting, loss of appetite, headache, insomnia, vivid dreams, and dry mouth.
Moderate side effects of carbidopa and Levodopa include confusion, hallucinations, mood changes (depression, anxiety), involuntary movements (jerking, dyskinesia, writhing or twitching), irregular heartbeat or palpitations, and fluctuations in motor response.
Rare but serious side effects include:
- Sudden sleep attacks.
- Gastrointestinal bleeding (vomiting blood, black stools)
- Severe allergic reaction (itching rash, swelling, trouble breathing)
- Worsening of glaucoma (blurred vision, eye pain)
- Signs of liver problems (yellowing of eyes, dark urine)
- Malignant melanoma. Skin cancer is higher in long-term users. Regular skin monitoring is necessary.
To avoid side effects, Syndopa CR 50/200mg should be used strictly under the guidance of a healthcare professional, with regular monitoring for side effects and drug interactions.
How to use?
Administration methods of the Syndopa cr 50 200 mg
The dosing is strictly recommended by a healthcare professional based on the severity of symptoms, age, and prior response to Parkinson’s medication. Typically, the tablets are taken 1 to 3 times daily, but timings and quantity vary among patients. Swallow the tablet whole with a glass of water. Avoid chewing or crushing the tablet, as this could affect the controlled-release mechanism. It is generally recommended to take this medication with meals to minimise gastrointestinal side effects. However, protein-rich foods (such as meat, milk, and beans) may reduce the absorption of the drug; therefore, it is essential to adjust the timing accordingly. Parkinson’s disease requires long-term treatment. Sudden discontinuation may abruptly withdraw, may worsen symptoms or trigger neuroleptic malignant syndrome (a rare but serious reaction).
What is Syndopa CR 50/200mg used for?
Syndopa CR 50/200mg contains carbidopa 50mg and levodopa 200mg in a controlled-release (CR) formulation. The CR matrix releases levodopa gradually over 4–6 hours — extending the duration of effect compared to immediate-release tablets and reducing dose frequency. It is used when immediate-release carbidopa/levodopa produces bothersome motor fluctuations (wearing-off), or for overnight coverage to prevent early-morning off (akinesia on waking). The higher 50mg carbidopa content ensures full peripheral inhibition even with the sustained-release levodopa delivery.
How is Syndopa CR 50/200mg different from immediate-release carbidopa/levodopa?
Syndopa CR 50/200 uses a polymer matrix to delay levodopa dissolution and absorption — providing slower plasma rise (peak at 1–2 hours vs. 30–60 minutes for IR), lower peak concentration, and longer effect (4–6 hours vs. 3–4 hours for IR). The lower peak reduces peak-dose dyskinesias in susceptible patients. However, the slower absorption means motor response is less predictable — on periods may be delayed or incomplete. Bioavailability of CR is approximately 70% of equivalent IR dose — so 200mg CR provides roughly 140mg levodopa equivalent. Doses must be increased by ~30% when switching from IR to CR.
How should Syndopa CR 50/200mg be dosed?
The standard dose is 1–2 tablets of Syndopa CR 50/200 (200–400mg levodopa CR) 2–3 times daily. NEVER crush, break, or chew Syndopa CR tablets — this destroys the controlled-release mechanism and delivers the full dose as an immediate bolus, risking dyskinesias. CR bioavailability is 70–75% of IR — if converting from IR carbidopa/levodopa, divide total IR daily levodopa by 0.7 to determine CR equivalent dose. The first morning dose should typically be IR to provide faster onset when patients wake in an off state.
Can Syndopa CR 50/200mg be used for overnight coverage in Parkinson's disease?
Yes — one of the primary uses of Syndopa CR 50/200 is an evening or bedtime dose to provide overnight levodopa coverage and prevent early-morning off (akinesia, rigidity, difficulty turning in bed that occurs in the early morning before the first daily dose takes effect). A bedtime dose of one Syndopa CR 50/200 tablet (200mg levodopa, slow-release) provides gradual overnight levodopa delivery. First morning immediate-release dose is still typically needed for fast-onset motor control on waking. This IR/CR combination approach is widely used in Parkinson's specialist centres.
Is Syndopa CR 50/200mg better than immediate-release for wearing-off?
Syndopa CR 50/200 partially addresses wearing-off by extending each dose's duration — reducing the frequency of wearing-off epiSodiumes. However, it does not eliminate wearing-off and may worsen dose predictability in patients who develop significant on-off fluctuations. For more reliable wearing-off management, combination strategies are preferred: adding entacapone (COMT inhibitor) to standard IR carbidopa/levodopa extends its duration while maintaining reliable onset. Deep brain stimulation (DBS) provides the most complete wearing-off elimination for eligible candidates.
What happens if Syndopa CR 50/200mg is crushed?
Crushing Syndopa CR 50/200 destroys the polymer-matrix controlled-release mechanism and converts it to an immediate-release dose. Instead of gradual levodopa release over 4–6 hours, the full 200mg levodopa dose is rapidly absorbed — producing a spike in plasma levodopa and significant risk of severe peak-dose dyskinesias. This can be acutely disabling and distressing. NEVER crush CR carbidopa/levodopa. If a patient is tube-fed or unable to swallow, a dispersible or liquid levodopa formulation should be prescribed instead of crushing CR tablets.
How does Syndopa CR 50/200mg compare to Stalevo (levodopa/carbidopa/entacapone)?
Syndopa CR 50/200 uses extended matrix release for longer effect. Stalevo (levodopa/carbidopa/entacapone) uses standard immediate-release carbidopa/levodopa with the added COMT inhibitor entacapone to extend levodopa half-life — a different mechanism. Stalevo provides faster onset than CR (similar to IR) with extended duration similar to CR — combining the best of both approaches. Stalevo is preferred when reliable fast onset AND prolonged duration are both needed. Syndopa CR is preferred when the goal is specifically reduced dosing frequency or overnight coverage.
Is Syndopa CR 50/200mg the same as Sinemet CR?
Yes. Syndopa CR 50/200 and branded Sinemet CR (carbidopa/levodopa CR 50/200) are bioequivalent controlled-release formulations of the same active ingredients. Syndopa CR is the generic version providing the same sustained-release Parkinson's disease motor management as Sinemet CR at significantly lower cost.
Can I order Syndopa CR 50/200mg from PremiumRxDrugs for delivery to Australia?
Yes. PremiumRxDrugs.com ships Syndopa CR 50/200mg to Australia, the USA, UK, and many other countries. Our genuine manufacturer-verified Parkinson's medications, competitive pricing, and free worldwide shipping on qualifying orders us them a trusted international pharmacy for controlled-release levodopa requirements.
What side effects are specific to controlled-release carbidopa/levodopa?
Syndopa CR-specific concerns: unpredictable motor response — on periods may be delayed or incomplete (slower absorption means variable motor control onset). Dose-dumping: any manipulation of CR tablet (crushing, extreme pH environments) risks rapid release and severe dyskinesias. Accumulation: CR's longer half-life means accumulation with repeated dosing is more pronounced than IR — dosing too frequently causes gradual dyskinesia build-up. Peak-dose dyskinesias are generally milder than with IR due to lower peak concentration. Switch back to IR if motor response becomes unacceptably unpredictable on CR formulation.
How does morning akinesia affect Syndopa CR 50/200mg dosing strategy?
Morning akinesia — inability to move well on waking before the first levodopa dose takes effect — is a major complaint for many Parkinson's patients. Since Syndopa CR has a delayed onset (1–2 hours), it is unsuitable as the first morning dose for patients with severe morning akinesia. The recommended strategy: first morning dose of fast-acting IR carbidopa/levodopa 25/100 (onset 30–60 minutes) to rapidly reverse morning off; subsequent daytime doses can be IR or CR. The bedtime Syndopa CR 50/200 provides gradual overnight coverage, reducing overnight and early-morning off while preserving fast-onset morning responsiveness.
Login
Sign Up
Login
Sign Up